Clinical trial for a better treatment for mycetoma starts in SudanClinical trial for a better treatment for mycetoma starts in Sudan
Clinical trial for a better treatment for mycetoma starts in Sudan[Khartoum, Sudan – 19 June 2017] First ever double-blind study for disease so neglected that it only recently was added to WHO list of neglected tropical diseases The first-ever double-blind, randomized clinical trial for an effective treatment for the severely neglected disease mycetoma has enrolled its first patient at the Mycetoma Research Centre (MRC) in Khartoum, Sudan.
GARDP at one: R&D programmes getting underwayGARDP at one: R&D programmes getting underway
GARDP at one: R&D programmes getting underwayGARDP has set up its team, scientific advisory committee, and R&D strategy. Three programmes are underway: neonatal sepsis, gonorrhoea, and an initiative to recover and connect the vital knowledge of scientists in antibiotic drug development. In recent weeks, both the G20 Health Ministers and outgoing WHO Director-General Margaret Chan have expressed support for GARDP and called for more R&D into drug-resistant infections.
NTD Summit 2017: this is not (yet) the endgameNTD Summit 2017: this is not (yet) the endgame
NTD Summit 2017: this is not (yet) the endgameBernard Pécoul, Executive Director, DNDi [May 2017] Ambitious targets serve the obvious purpose of galvanising the NTD community around a shared goal, and the London Declaration succeeded in bringing new actors to the table and casting a much-needed spotlight on the neglect of these diseases. But the job is far from done, and we should not be lulled into a sense of security or complacency by too much celebrating of good news.
New open source project engages universities in neglected diseases drug discoveryNew open source project engages universities in neglected diseases drug discovery
New open source project engages universities in neglected diseases drug discovery[London and New York – May 3, 2017] Indian, UK and US students to help discover desperately-needed drug leads for visceral leishmaniasis The non-profit research and development organisation Drugs for Neglected Diseases initiative (DNDi) has launched a collaborative project with five universities in India, the UK, and the US to harness the capacity of university teaching laboratories and task students with discovering potential new drugs for patients living with neglected diseases.
- Clinical trial for a better treatment for mycetoma starts in Sudan 19 June 2017
- New open source project engages universities in neglected diseases drug discovery 3 May 2017
- Merck joins DNDi’s “Drug Discovery Booster” to accelerate discovery of new treatments for neglected diseases 19 April 2017
- First large-scale survey of Chagas disease in the United States confirms that the “Silent Killer” is a major public health challenge for the country 13 April 2017
- Daiichi Sankyo announces collaborative research on drugs for neglected diseases 14 February 2017
- Global Health NOW: “Tapping student potential: Q&A on DNDi’s Open Synthesis Network with Ben Perry” 13 June 2017
- Huffington Post India: “How the introduction of a new drug in India will greatly help children living with HIV” 6 June 2017
- Takeda: “グローバルヘルス技術振興基金第二期への資金拠出について” 1 June 2017
- Business Daily: “Crossing fingers for child-friendly ARVs” 30 May 2017
- TagesWoche: “Die UNO fordert alternative Finanzierungen für Medikamente” 27 May 2017
- Safety and efficacy of short course combination regimens with AmBisome®, miltefosine, paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh by Rahman R, Goyal V, Haque R, Jamil K, Faiz A, Samad R, Ellis S, Balasegaram M, den Boer M, Rijal S, Strub-Wourgaft N, Alves F, Alvar J, Sharma B. PLOS NTDs, June 2017
- IFN-g, IL-2, IP-10, and MIG as biomarkers of exposure to leishmania spp., and of cure in human visceral leishmaniasis by Ibarra-Meneses AV, Ghosh P, Hossain P, Chowdhury R, Mondal D, Alvar J, Moreno J and Carrillo E. Frontiers in Cellular and Infection Microbiology, May 2017
- 7 substituted 2 Nitro-5,6-dihydroimidazo[2,1 b][1,3]oxazines: novel antitubercular agents lead to a new preclinical candidate for visceral leishmaniasis by Thompson A, O’Connor PD, Marshall AJ, Yardley V, Maes L, Gupta S, Launay D, Braillard S, Chatelain E, Franzblau SG, Wan B, Wang Y, Ma Z, Cooper CB, Denny WA. Journal of Medicinal Chemistry, May 2017
- Infectivity of post-kala-azar dermal leishmaniasis patients to sand flies: revisiting a proof of concept in the context of the kala-azar elimination program in the Indian subcontinent by Molina R, Ghosh D, Carrillo E, Monnerat S, Bern C, Mondal D, Alvar J. Clinical Infectious Diseases, May 2017
- Estimación de la demanda de medicamentos antichagásicos: una contribución para el acceso en América Latina (Estimating demand for anti-Chagas drugs: a contribution for access in Latin America) by Costa Chaves G, Abi-Saab Arrieche M, Rode J, Mechali D, Ouverney Reis P, Alves RV, Stobbaerts E, Girón Aguilar N, Ribeiro I. Pan American Journal of Public Health, April 2017
- WorldLeish 6
6th World Congress on LeishmaniasisMay 16-20, 2017 Toledo, Spain The WHO ColIaborating Centre for Leishmaniasis at the Instituto de Salud Carlos III, Madrid and the Drugs for Neglected Diseases initiative, Geneva joined efforts to co-organize the WorldLeish-6 Congress.
- 2nd Symposium on Medicinal Chemistry for Global Health June 18-20, 2017 GlaxoSmithKline, Tres Cantos, Madrid, Spain Ben Perry, NTD Drug Discovery Booster Project Manager and Charles Mowbray, Head of Discovery, DNDi, presented on the NTD Discovery Booster, aminopyrazoles and NTDs.
- IAS 2017
9th IAS Conference on HIV ScienceJuly 23-26, 2017 Paris, France Isabelle Andrieux-Meyer, Paediatric HIV/HCV Team Leader at DNDi, will present on DNDi's work on HCV.
- XXV Brazilian Parasitology Congress September 3-6, 2017 Búzios, Rio de Janeiro, Brazil DNDi will present an abstract on LOLA hit-to-lead results.